Atossa Therapeutics ATOS shares are trading lower on Thursday.
The company announced it has contracted with Avance Clinical to conduct a clinical study for its AT-301 Nasal Spray for the company's second coronavirus therapeutics development program.
Atossa Therapeutics is a clinical-stage pharmaceutical company operating in the US. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The clinical-Stage Programs of the company includes delivery of therapeutics through microcathe
Atossa Therapeutics shares were trading down 0.51% at $3.94 on Thursday. The stock has a 52-week high of $4.69 and a 52-week low of 76 cents.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
